MI HR0285

Urges the U.S. Congress to pass the Kidney PATIENT Act of 2023 to delay implementation of new payment policies for oral-only phosphate binder drugs used to treat end-stage renal disease (ESRD)

Identifies that 808,536 individuals in the United States live with ESRD, with over one million Michigan adults having chronic kidney disease, and notes African Americans represent one-third of dialysis patients despite being 13 percent of the U.S. population

Opposes a Centers for Medicare & Medicaid Services policy scheduled to take effect January 1, 2025, that would shift payment for ESRD-related oral-only drugs from Medicare Part D into the bundled ESRD payment system for dialysis sessions

Delays the payment methodology change until January 1, 2033, or until an intravenous alternative is FDA-approved, whichever occurs first, to protect patient access and prevent disproportionate impact on minority and low-income communities

Directs transmission of this resolution to the Speaker of the U.S. House of Representatives, President of the U.S. Senate, and Michigan's congressional delegation